Table S2. Meta-analysis of the association between PLR and clinicopathological parameters of BC with NACT.

Variable	No. of studies	No. of patients	Effects model	OR (95% CI)	p	Heterogeneity	
						I^2	P_H
Age (Yong vs. Old)	9	3273	Fixed	0.86(0.79-0.93)	<0.001	40.60%	0.096
Histologic type (Ductal vs. Others)	4	1520	Fixed	0.97(0.94-1.01)	0.147	7.20%	0.357
Grade (G1+G2 vs. G3+unknown)	4	1692	Fixed	0.96(0.91-1.02)	0.203	0.00%	0.439
T stage (T1–T2 vs. T3–T4)	6	2178	Random	1.05(1.00-1.11)	0.035	70.30%	0.005
Lymph node metastasis (No vs. Yes)	5	2341	Fixed	0.97(0.88-1.06)	0.440	0.00%	0.952
ki-67 (<14 vs. >=14)	7	2783	Fixed	0.99(0.90-1.09)	0.771	0.00%	0.458
Hormone Receptor (− vs. ＋)	6	2049	Fixed	0.94(0.84-1.06)	0.309	0.00%	0.526
HER-2 (− vs. ＋)	7	2023	Random	0.91(0.76-1.09)	0.293	69.20%	0.003
Molecular subtype (Luminal vs. TriNeg + HER-2+)	8	2143	Fixed	0.99(0.92-1.07)	0.845	15.20%	0.310
Menopausal status (Pre vs. Post)	5	1604	Fixed	0.83(0.76-0.90)	<0.001	50.80%	0.087

Abbreviations: OR: odds ratio; 95% CI: 95% confidence interval; P_h: *p* values of Q test for heterogeneity test.